CoChat

Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence

The DOI matches its Crossref record; 206 of the 208 references it cites were found in a registry or an index.

Abstract

As the prevalence of diabetes continues to climb, the number of individuals living with diabetic complications will reach an unprecedented magnitude. The emergence of new glucose-lowering agents - sodium-glucose cotransporter 2 inhibitors and incretin therapies - has markedly changed the treatment landscape of type 2 diabetes mellitus. In addition to effectively lowering glucose, incretin drugs, which include glucagon-like peptide 1 receptor (GLP1R) agonists and dipeptidyl peptidase 4 (DPP4) inhibitors, can also reduce blood pressure, body weight, the risk of developing or worsening chronic kidney disease and/or atherosclerotic cardiovascular events, and the risk of death. Although kidney disease events have thus far been secondary outcomes in clinical trials, an ongoing phase III trial in patients with diabetic kidney disease will test the effect of a GLP1R agonist on a primary kidney disease outcome. Experimental data have identified the modulation of innate immunity and inflammation as plausible biological mechanisms underpinning the kidney-protective effects of incretin-based agents. These drugs block the mechanisms involved in the pathogenesis of kidney damage, including the activation of resident mononuclear phagocytes, tissue infiltration by non-resident inflammatory cells, and the production of pro-inflammatory cytokines and adhesion molecules. GLP1R agonists and DPP4 inhibitors might also attenuate oxidative stress, fibrosis and cellular apoptosis in the kidney.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41581-020-00367-2

Cites

206 of 206 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 206 references

Cited by

See all 216

Metadata

Authors
Alicic, R. Z., Cox, E. J., Neumiller, J. J., & Tuttle, K. R.
Affiliations
  • University of Washington (US)
  • Washington State University Spokane (US)
Corresponding author
Tuttle, Katherine R.
Venue
Nature Reviews Nephrology
Published
2020-11-20
Volume
17
Issue
4
Pages
227-244
ISSN
  • 1745-8323 (ISSN-L)
  • 1759-5061
  • 1759-507X
OpenAlex
W3102119644
Cited by
193
References
208
Citations by year
2026: 26 · 2025: 45 · 2024: 33 · 2023: 35 · 2022: 33 · 2021: 21
FWCI
3.63
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Nature Reviews Nephrology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
Keywords
incretin-based therapy, diabetic nephropathy, GLP-1 receptor agonists, DPP-4 inhibitors, type 2 diabetes, renal protection, innate immunity, inflammation, mononuclear phagocytes, inflammatory cytokines, oxidative stress, renal fibrosis, apoptosis, blood pressure reduction, cardiovascular risk
MeSH terms
Diabetes Mellitus, Type 2, Diabetic Nephropathies, Humans, Hypoglycemic Agents, Kidney, Biomarkers, Dipeptidyl Peptidase 4, Glucagon-Like Peptide 1, Incretins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence. https://app.cochat.ai/papers/10.1038/s41581-020-00367-2
The paper
Alicic, R. Z., Cox, E. J., Neumiller, J. J., & Tuttle, K. R. (2021). Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence. Nature Reviews Nephrology. https://doi.org/10.1038/s41581-020-00367-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.